Navis Capital Partners has closed two Southeast Asia healthcare deals, with agreements to buy Indonesia-based medical devices distributor Tawada Healthcare and Vietnam’s Hanoi French Hospital.
The Carlyle Group has re-listed Solasto Corporation on the Tokyo Stock Exchange, four-and-a-half years after privatizing the medical staffing business, which was previously known as NIC Corp.
China Everbright has invested an undisclosed amount in Chinese healthcare conglomerate Neusoft Holdings through its renminbi-denominated mezzanine fund.
Indian hospital chain Aster DM Healthcare has filed for an IPO, seeking to raise at least INR6.1 billion ($89 million) and providing partial exits for its PE backers Olympus Capital Asia and India Value Fund Advisors (IVFA).
The Carlyle Group has hired Jesse Wu, the former chairman of Johnson & Johnson China, as a senior advisor to the firm’s Asia buyout team.
OrbiMed will consolidate its control of Canada-listed clinical equipment producer Response Biomedical in an C$11.1 million ($8.6 million) take-private deal including participation by Shanghai Runda Medical Technology.
Chinese healthcare-focused GP HighLight Capital has led a RMB50 million ($7.6 million) Series B round for Jun He Tang, a traditional Chinese medicine (TCM) business, followed by existing investor Qiming Venture Partners.
Chinese drug maker Shenzhen Hepalink Pharmaceutical has agreed to commit $60 million to TPG Capital’s latest biotech fund.
Indian venture capital firm Lok Capital has reached a first close of $40.5 million for its third fund, which is targeting a $100 million total corpus within 12-18 months.
The International Finance Corporation (IFC), the investment arm of the World Bank, will anchor a planned $200 million funding round for India's Glenmark Pharmaceuticals, committing up to $75 million.
IBM has launched an accelerator in Singapore that will help Asia Pacific start-ups commercialize blockchain technology and the cognitive computing system known as Watson.
GPs are finding opportunity in Japan’s economic stagnancy and dramatic demographic trends, but embracing this massive market will require a sharper focus on planning, as well as patience and poise
Australian VC firm Starfish Ventures has joined a $17.5 million round for Aktana, a US and Japan-based marketing services provider looking to consolidate its Asian footprint.
Ligang Zhang, founder and CEO of US-listed Chinese company iKang Healthcare Group, and a consortium led by Meinian Onehealth Healthcare Group, have withdrawn their privatization proposals for iKang after the company received a new offer from Yunfeng Capital.
Chinese healthcare services provider iKang Healthcare Group, which became the take-private target of a string of PE and strategic investors, has received a new competing bid from Yunfeng Capital.
Warburg Pincus has agreed to make another partial exit from China Biologic Products, a US-listed bio-pharmaceutical developer, generating proceeds of about $308 million.
Eight Roads Ventures has led a $17.5 million Series B round for Japanese wheelchair and personal mobility device developer Whill.
Healthcare-focused GP Lily Asia Ventures and SBCVC have participated in a RMB100 million ($15 million) Series A round for 360 Haoyao, an online drug seller established by Chinese software company Qihoo360 Technology.
Healthcare specialist Vivo Capital has closed its latest Sino-US venture capital fund with around $100 million in commitments. The vehicle will focus on early-stage investments.
The International Finance Corporation (IFC), the investment arm of the World Bank, has committed $68 million to Indian clinic chain Apollo Health and Lifestyle (AHL).
Ping An Good Doctor, a healthcare-focused mobile app controlled by Chinese Ping An Insurance Group, has raised $500 million in a Series A round of funding at a valuation of $3 billion.
WI Harper Group has closed its eighth venture capital fund, which targets early-stage investments in Asia-focused companies, at $175 million.
Hong Kong-listed drug maker Fosun Pharmaceutical has made a non-binding proposal to acquire Gland Pharma, an Indian pharmaceutical developer backed by KKR.
China Everbright has acquired a 67.3% stake in Beijing Huichen Nursing Home Management, a healthcare services provider for more than 10,000 Chinese seniors.